SOL-257, an experimental gene therapy developed by SOLA Biosciences, has shown encouraging preclinical results by slowing disease progression and significantly extending survival in a mouse model of amyotrophic lateral sclerosis (ALS) through targeting toxic, misfolded TDP-43 protein that drives neuronal damage. The therapy, presented at a major neuromuscular disease research summit, works by harnessing the body’s own cellular machinery to repair or clear the harmful protein, offering a novel approach with broad potential for ALS treatment. Read more (via ALS News Today)